ASCO supports testing for PIK3CA to identify candidates for alpelisib, gBRCA1/2 for PARP inhibitors, and PD-L1 in TNBC for immune checkpoint inhibitor therapy; it also considers Microsatellite Instability–High (MSI-H)/Deficient Mismatch Repair (dMMR), Tumor Mutational Burden (TMB)-high, and Neurotrophic Tyrosine Receptor Kinase (NTRK) fusions actionable when matching therapies are available, but does not recommend circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) for routine monitoring [300]. This evidence concerns the gene CD274 and neoplasm.